Table 3.

Patients given second dose of study drug or alternative sedatives, with adverse event report, and observed asleep.

	Study group						P value
	Midazolam (N = 56)		Olanzapine (N = 54)		Haloperidol (N = 57)
	n	(%)	n	(%)	n	(%)
Administered second dose of study drug or alternative sedatives	18	(32)	16	(30)	23	(40)	0·46
Administered second dose	13	(23)	15	(28)	18	(32)	0·61
Administered alternative sedatives	9a	(16)	6	(11)	7b	(12)	0·72
Midazolam	6	(67)	2	(33)	3	(43)
Haloperidol	2	(22)	4	(67)	2	(29)
Diazepam	3	(33)	0	–	2	(29)
Lorazepam	1	(11)	0	–	1	(14)
With adverse event	2	(4)	3	(6)	3	(5)	0·91
Oxygen desaturation (<90%)	2	(4)	1	(2)	1	(2)
Dry month	0	–	2	(4)	0	–
Dystonia	0	–	0	–	1	(2)
Cardiac arrest	0	–	0	–	1	(2)
ECG obtained	(N = 52)		(N = 52)		(N = 56)
QTc prolongation	12	(23)	9	(17)	13	(23)	0·59
Fell asleep after treatment	28	(50)	10	(19)	17	(30)	<0·01

*ECG, 12-lead electrocardiogram; QTc, corrected QT interval.

An adverse event is any untoward medical occurrence in a patient after administration of a medicinal product, which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavourable and unintended sign (for example, an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to study drug.

^aThree patients were given two alternative sedative drugs.

^bOne patient was given two alternative sedative drugs.